Ulrich Granzer
Chief Executive Officer chez Granzer Regulatory Consulting & Services
Profil
Ulrich Granzer is the founder of Granzer Regulatory Consulting & Services, established in 2002.
He is currently the Director at Cardior Pharmaceuticals GmbH, Venture Partner at Wellington Partners GmbH since 2004, and Member-Supervisory Board at APEIRON Biologics AG since 2021.
Dr. Granzer's former positions include Chairman-Supervisory Board at Biofrontera AG from 2016 to 2021, Director-Regulatory Affairs at Bayer AG, GSK Plc, and Knoll AG, Director-Supervisory Board at Immatics Biotechnologies GmbH from 2009 to 2012, and Head-Regulatory Affairs at Bayer Pharma AG.
Dr. Granzer holds a doctorate from Eberhard Karls Universität Tübingen and a graduate degree from Philipps University of Marburg.
Postes actifs de Ulrich Granzer
| Sociétés | Poste | Début |
|---|---|---|
| Granzer Regulatory Consulting & Services | Chief Executive Officer | 01/01/2002 |
Wellington Partners GmbH
 Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Private Equity Investor | 01/01/2004 |
Cardior Pharmaceuticals GmbH
 Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Director/Board Member | - |
APEIRON Biologics AG
 APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | Director/Board Member | 21/06/2021 |
Anciens postes connus de Ulrich Granzer
| Sociétés | Poste | Fin |
|---|---|---|
| BIOFRONTERA AG | Chairman | 14/12/2021 |
| BAYER AG | General Counsel | - |
Knoll AG
 Knoll AG Pharmaceuticals: MajorHealth Technology Part of BASF SE, Knoll AG develops pharmaceuticals. The private company is based in Haren, Germany. | General Counsel | - |
| GSK PLC | General Counsel | - |
Bayer Pharma AG
 Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Bayer Pharma AG engages in the development and production of prescription drugs for the treatment of cardiovascular diseases and women's illnesses, as well as special therapy in the areas of oncology, hematology, and ophthalmology. It also offers medical equipment used in diagnostic imaging with applications in the field of radiology. The company was founded on March 9, 1965 and is headquartered in Berlin, Germany. | General Counsel | - |
Formation de Ulrich Granzer
| Eberhard Karls Universität Tübingen | Doctorate Degree |
| Philipps University of Marburg | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BAYER AG | Health Technology |
| GSK PLC | Health Technology |
| BIOFRONTERA AG | Health Technology |
| Entreprise privées | 7 |
|---|---|
Knoll AG
Knoll AG Pharmaceuticals: MajorHealth Technology Part of BASF SE, Knoll AG develops pharmaceuticals. The private company is based in Haren, Germany. | Health Technology |
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Finance |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Bayer Pharma AG
Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Bayer Pharma AG engages in the development and production of prescription drugs for the treatment of cardiovascular diseases and women's illnesses, as well as special therapy in the areas of oncology, hematology, and ophthalmology. It also offers medical equipment used in diagnostic imaging with applications in the field of radiology. The company was founded on March 9, 1965 and is headquartered in Berlin, Germany. | Health Technology |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | Health Technology |
| Granzer Regulatory Consulting & Services | |
Cardior Pharmaceuticals GmbH
Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Health Technology |
